Evidence map›Paper›PMID 36414814›Full record

SynthesisJournal of cancer research and clinical oncology2023

Progress in the treatment of urethral adenocarcinoma.

Jiamin Guo, Xiuping Liang, Yichen Zheng, Ji Ma

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jiamin Guo *Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Xiuping Liang *Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Yichen ZhengDepartment of Medical Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Ji MaDepartment of Medical Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. majimrn@163.com.
Sichuan University · CN

Funding

Key Research and Development Project of Sichuan Province 2020YFS0273Scientific Research Project of Sichuan Health Commission 20PJ008
6 · The paper itself

Abstract

backgroundUrothelial adenocarcinoma (UA) is a rare subtype of primary urothelial carcinoma, which is more common in women and has a poor prognosis. Because of their low incidence, most of the existing literature is based on case reports and there is a lack of comprehensive literature on this type of tumor. PURPOSE: This article provides a comprehensive and systematic review of the epidemiology, pathological types, treatment, and prognosis of UA. Especially in the treatment section, we reviewed the various treatment methods including surgery, radiotherapy, chemotherapy, immunotherapy and molecular targeted therapy. This review aims to provide a theoretical basis for the clinical diagnosis and management of UA.

methodsWe reviewed the relevant literature of UA from Pubmed.

conclusionThere is no standard treatment for UA. Multidisciplinary therapy, including surgery, radiotherapy and chemotherapy, is the current trend. Immunotherapy and molecular targeted therapy will also become viable options for the treatment of UA in future.

Indexed as

AdenocarcinomaCarcinoma, Transitional CellUrethral NeoplasmsUrinary Bladder NeoplasmsFemaleHumansPrognosisEpidemiologyHistopathologyPrognosisTreatmentUrethral adenocarcinoma

Identifiers

PMID36414814
PMCPMC11796704
OpenAlexW4309648276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.